Evidence map›Paper›PMID 39659236›Full record

ArticleCNS neuroscience & therapeutics2024

CCN1 Promotes Mesenchymal Phenotype Transition Through Activating NF-κB Signaling Pathway Regulated by S100A8 in Glioma Stem Cells.

Xing Guo, Shuhua Guo, Feng Tian, Zijie Gao, Yang Fan, Chuanxin Wang, Shuo Xu

Abstract read
In one paragraph

Article in CNS neuroscience & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xing GuoDepartment of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan, Shandong, China.ORCID 0000-0001-8431-8590
Shuhua GuoDepartment of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China.ORCID 0009-0007-9872-9332
Feng TianDepartment of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China.
Zijie GaoDepartment of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan, Shandong, China.
Yang FanDepartment of Neurosurgery, The First Affiliated Hospital of Shandong First Medical University &Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
Chuanxin WangDepartment of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China.
Shuo XuDepartment of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan, Shandong, China.

Funding

Key Research and Development Program of Shandong Province 2021ZLGX02National Key Research and Development Program of China 2022YFC2406404National Key Research and Development Program of China 2023YFC2413004National Natural Science Foundation of China 82272413Natural Science Foundation of Shandong Province ZR2023MH036Taishan Scholarship Young Expert Program tsqn201909174Youth Innovation of Colleges and Universities of Shandong Province of China 2023KJ023
6 · The paper itself

Abstract

backgroundThe presence of glioma stem cells (GSCs) and the occurrence of mesenchymal phenotype transition contribute to the miserable prognosis of glioblastoma (GBM). Cellular communication network factor 1 (CCN1) is upregulated within various malignancies and associated with cancer development and progression, while the implications of CCN1 in the phenotype transition and tumorigenicity of GSCs remain unclear.

methodsData for bioinformatic analysis were obtained from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases. A range of primary GBM and GSC cell models were then used to demonstrate the regulatory role of CCN1 via the phenotype validation, tumor sphere formation assays, extreme limiting dilution assays (ELDA), and transwell assays. To screen out the downstream signaling pathway, we employed high-throughput RNA-seq. Intracranial xenograft GSC mouse models were used to investigate the role of CCN1 in vivo.

resultsAmong the CCN family members, CCN1 was highly expressed in MES-GBM/GSCs and was correlated with a poor prognosis. Both in vitro and in vivo assays indicated that knockdown of CCN1 in MES-GSCs reduced the tumor stemness, proliferation, invasion, and tumorigenicity, whereas CCN1 overexpression in PN-GSCs exhibited the opposite effects. Mechanistically, CCN1 triggered the FAK/STAT3 signaling in autocrine and paracrine manners to upregulate the expression of S100A8. Knockdown of S100A8 inactivated NF-κB/p65 pathway and significantly suppressed the tumorigenesis of MES-GSCs.

conclusionOur findings reveal that CCN1 may be an important factor in the enhanced invasiveness and MES phenotype transition of GSCs and highlight the potential to target CCN1 for treating GBM.

Indexed as

Brain NeoplasmsCalgranulin ACysteine-Rich Protein 61GliomaNeoplastic Stem CellsNF-kappa BSignal TransductionAnimalsCell Line, TumorEpithelial-Mesenchymal TransitionHumansMiceMice, NudePhenotypeCalgranulin ACCN1 protein, humanCysteine-Rich Protein 61NF-kappa BCCN1glioblastomaglioma stem cellsmesenchymal phenotype transitionS100A8

Identifiers

PMID39659236
PMCPMC11632201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.